Publications by authors named "Timothy P Burkholder"

Claim this Profile
D
Discovery of chiral dihydropyridopyrimidinones as potent, selective and orally bioavailable inhibitors of AKT.
Saravanan Parthasarathy, Kenneth Henry, Huaxing Pei, Josh Clayton, Mark Rempala, Timothy P Burkholder

Bioorg Med Chem Lett· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of a Highly Selective NAMPT Inhibitor That Demonstrates Robust Efficacy and Improved Retinal Toxicity with Nicotinic Acid Coadministration.
Genshi Zhao, Colin F Green, Yu-Hua Hui, Lourdes Prieto, Robert Shepard, Timothy P Burkholder

Mol Cancer Ther· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and synthesis of a novel series of [1-(4-hydroxy-benzyl)-1H-indol-5-yloxy]-acetic acid compounds as potent, selective, thyroid hormone receptor β agonists.
Timothy P Burkholder, Brian E Cunningham, Joshua R Clayton, Peter A Lander, Matthew L Brown

Bioorg Med Chem Lett· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacological inhibition of nicotinamide phosphoribosyltransferase (NAMPT), an enzyme essential for NAD+ biosynthesis, in human cancer cells: metabolic basis and potential clinical implications.
Bo Tan, Debra A Young, Zhao-Hai Lu, Tao Wang, Timothy I Meier, Timothy P Burkholder

J Biol Chem· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of LY2457546: a multi-targeted anti-angiogenic kinase inhibitor with a novel spectrum of activity and exquisite potency in the acute myelogenous leukemia-Flt-3-internal tandem duplication mutant human tumor xenograft model.
Timothy P Burkholder, Joshua R Clayton, Mark E Rempala, James R Henry, John M Knobeloch

Invest New Drugs· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose study of the multikinase inhibitor, LY2457546, in patients with relapsed acute myeloid leukemia to assess safety, pharmacokinetics, and pharmacodynamics.
Volker Wacheck, Michael Lahn, Gemma Dickinson, Wolfgang Füreder, Renata Meyer, Timothy P Burkholder

Cancer Manag Res· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Developing and applying a gene functional association network for anti-angiogenic kinase inhibitor activity assessment in an angiogenesis co-culture model.
Yuefeng Chen, Tao Wei, Lei Yan, Frank Lawrence, Hui-Rong Qian, Timothy P Burkholder

BMC Genomics· June 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The development of potent and selective bisarylmaleimide GSK3 inhibitors.
Thomas A Engler, Sushant Malhotra, Timothy P Burkholder, James R Henry, David Mendel

Bioorg Med Chem Lett· February 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Substituted 3-imidazo[1,2-a]pyridin-3-yl- 4-(1,2,3,4-tetrahydro-[1,4]diazepino-[6,7,1-hi]indol-7-yl)pyrrole-2,5-diones as highly selective and potent inhibitors of glycogen synthase kinase-3.
Thomas A Engler, James R Henry, Sushant Malhotra, Brian Cunningham, Kelly Furness, Timothy P Burkholder

J Med Chem· July 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis